8-K
filed June 22, 2026, 4:05 PM ET
ticker ALLO
CIK 0001737287
other material
confidence high
sentiment neutral
materiality 0.70
Allogene shareholders approve doubling authorized shares to 800M; files $135M ATM offering
Allogene Therapeutics, Inc.
- Stockholders approved increase of authorized common shares from 400M to 800M, effective June 18, 2026.
- Advisory 'say-on-pay' vote approved; board adopts annual frequency for future advisory votes.
- Company filed prospectus supplement for up to $135M in common stock sales via ATM with TD Securities.
- All three Class II director nominees (Messemer, Sato, Witte) re-elected with strong support.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2026-06-18 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 213,098,167 11,951,256 3,375,985 54,299,010
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Allogene Therapeutics, Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares at the 2026-06-18 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares The Company’s stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 221,767,995 6,535,254 122,159 54,299,010
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, Say-On-Pay Vote Frequency at the 2026-06-18 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 3. Approval, on an Advisory Basis, Say-On-Pay Vote Frequency The Company’s stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 224,054,368 228,313 757,992 3,384,735 54,299,010
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Allogene Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 5. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 282,022,884 503,156 198,378 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Allogene Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-18
Exact text from the filing
Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Deborah Messemer 202,325,767 26,099,641 54,299,010 Vicki Sato, Ph.D. 202,326,299 26,099,109 54,299,010 Owen Witte, M.D. 189,310,484 39,114,924 54,299,010
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.